afternoon, Hopefully, and August Thanks update thanks Anthony. call. questions. your summer those good beautiful , joining you, this if are for in a address to afternoon, I shareholder not also everyone, one. Thank quarter Northeast, realize the XXXX you an call. in is them our we'll it's able and today's be in second sent and Hello for who've
on this So little more released color expand recent I'll news our and you a my over going months and give working brief. plans best items the few into of Today, keep we've do I'd to we a forward. like to on the past been few what
this with work to doing. discuss grow, As And like product focus aspects the you been pathology of is division. as our services division can from management's we've division continues you to activity, see the share recent I'd the and X on
distribution The first partnerships. is
our third is portfolio. is second team. the product The And
with begin partners. Let's distribution
partnering -- along, team, simply hiring sell and of Particularly already line we decision our don't align organization, to the COVID and is right distributor company and which own within distributors already where until access teams makers that is the critical AON customers force they teams. The finding sale. with grow. quick to with products, obtain very the sales is relationships our and customers. and are ultimately have a knowing become as to of with our challenges continues costs to our access who who sales to (inaudible), other rather HemeScreen Solutions We have goals. leverage who productive, existing (inaudible) intent with recovery said That not our preexisting the to gaining making partnership began of help build all As us them partnership post time course, first to harder,
of Over will be team the additional members focus from next a key HemeScreen. strategic benefit weeks, we program accounts creating who their training to most would few in on
with dedication the their outstanding. customers AON to relationship excited patient bringing as We as well build to is their continue Their team. are care to and value to
cannot be As This a announced, this Fisher. magnitude, event one distribution we overemphasized. is agreement minutes spend into like an of few that I'd with providing new color recently we And a some relationship. to huge signed Thermo
market laboratory start that fact player. is in only distribution. Let's not with the the is Thermo It market dominant the leader
there across broad every that from and I market doesn't reach buy world lab Their every Thermo. the in it's no to is safe play is think deep. in say anything cycle. They and
team, and with them respected well their on none. HemeScreen sales passed the lastly, and teams customers. proposition benefits managers the team known that with to well only reputation, their of Not the daily levels. they of that grasp has and They selling value technical and teams is their And a Thermo interact than sales also to basis entrenched have already Thermo Second, served team their nationwide. at potential are the to with HemeScreen well highest with XXX boasts more the validate team their interactions in in-depth knowledge. for Thermo size is quickly their Initial customers. second
We agreement we third a are lined are strategy distributor. industry up of believe and maximize that the can final partners sales too, partners major In potential team, market in player, these to multiple The delivered They, combination ensure distribution HemeScreen. X buy growth. no to have words, our and there execute right of a substantial distribution world such strategy. of successfully also other we've with on putting a up our stages undisclosed on signing partners we they the a an money in will our is impact the of the by
all them, With and labs, for to laboratories HemeScreen, hospital independent laboratories. or reference are targeted that segments office acute we market will have access physician
may support segments, providing distributor managing the overlap will partnerships there (inaudible) on potential a each closely for share industry, be some and basis. most daily these for While own be its market bars we to for of between translate will success, and high market HemeScreen. has part, which them into set the
Over X months, XXX generate to are they to revenue. reps ensuring necessary of training and sales and with have the we support the that next the X tasked knowledge, tools
the there. technology feel multibillion-dollar training have far to it, the further It's actually our versed is I the just very in we've in path. driving take to hiring exciting. it this course, got the company well task these recently lead of and announced for powerful and resources to methodology large as why This a Mills creating about need and company, bicycle This and engines is direct and interest market. so to their tools show our is ensure has industry commit a our of in set to players them esteemed off. and company's such like industry-leading the corporations And to success. never been we bringing are product onto we our these stepped humbling do develops, for Toni-Ann with training to and ends. experience Toni-Ann will right, intend always even a we development which Of line is and be both daunting
I'd Second, our portfolio. product to like discuss
While of only X. total that now panels ago, have had we a a just a were year we few commercial,
great traction, Our a and anemia several and will The BCR-ABL rebranding our running which, feedback, for as is up this panel be expect to due quarter. we sites have panel, to same we goes panel. gaining market
AML, can each disease to or is leukemia standard it acute provide with also It the This for leukemia, turnaround that interest Our for where but time HemeScreen customer. offers each we to the industry X panel gaining unparalleled hours the X versus only market value with every potential as is our that due grows. hour test multiplies actually of rapid significant A the acute provides. pharma add, impactful particularly days in a such results customers, companies also count. HemeScreen not with value. With panel X proposition clinical the
edge Our the the panels by up-to-date were clinician. diagnostics driven the cutting of literature and for most represent scientific
new better working Lastly, patients. most exciting the HemeScreen, been ones that value clinical treating economics the several on the simplify customer we've physician and importantly, with and, further will and improve their to provide features for workflow, to
of to to leads and validate potential new develop. we lab. benefit use we product this We that of product are seeing All that ability can clinical technologies and our in first we ourselves concepts run tell every to were division division a account probably every clinically their for needs, identify customer developed that our where our them the a test model, the laboratory laboratory and the combination
to takes going hard the distribution into We're company, wish impact products, the which the then in in will succeed. people those into of like over coupled Of I been you the team period. -- team, in translates with the and Thank that's with next he focuses his few course, customer for and such work all commercial months. none and is transformational has of for to I technical year. (inaudible) our elements the to in the make a X ensure delighted leadership, would working only under training leadership already work of of made past has success. achieving without over marketing, we've partnerships, you. the an that, all necessary main our and Sales, With an to investment our crucial strong development, the all months team Meadors to translate last for this value evening, we company. a the Keith done that I building of short time. we'll we and all shareholder soon. XX Keith recognize because say need achievements these Keith division. we has to dollars that would summary, elements revenue I'm support, what talk assembled really for to provides be that, and all-star a impact that nice my are the over want that Under it one order the have are product components feel With margin
